Blog
RSS FeedPosted by Michael Wonder on 19 Jun 2019
Health Canada approves Hemlibra for haemophilia A patients without factor VIII inhibitors
18 June 2019 - Hemlibra is the only treatment that can be self-injected subcutaneously once weekly for patients with hemophilia A ...
Posted by Michael Wonder on 30 May 2019
Health Canada approves Tecentriq (atezolizumab) combination therapy for first-line treatment of metastatic non-squamous non-small cell lung cancer
29 May 2019 - Data show this new option can help some patients with metastatic non-small cell lung cancer live significantly ...
Posted by Michael Wonder on 30 May 2019
Janssen announces Health Canada approval of Tremfya One-Press (guselkumab) - a patient-controlled injector for adults with moderate-to-severe plaque psoriasis
29 May 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that Health Canada has approved Tremfya One-Press, ...
Posted by Michael Wonder on 23 May 2019
Health Canada approves Mylan and Biocon's Ogivri, the first trastuzumab biosimilar, for the treatment of HER2-positive breast and gastric cancers
22 May 2019 - Ogivri is a part of Mylan's robust portfolio of 20 biosimilar and insulin analog products. ...
Posted by Michael Wonder on 17 May 2019
Health Canada approves injectable hydromorphone to treat opioid addiction
16 May 2019 - Canada is first country to approve the pain drug for severe opioid use disorder, says Health ...
Posted by Michael Wonder on 09 May 2019
First and only PARP inhibitor, Lynparza (olaparib) approved as a first-line maintenance therapy treatment in BRCA mutated advanced ovarian cancer
8 May 2019 - AstraZeneca and Merck's Lynparza reduced the risk of disease progression or death by 70% compared to ...
Posted by Michael Wonder on 04 May 2019
Seattle Genetics announces progress in expanding Adcentis (brentuximab vedotin) indications in Canada
3 May 2019 - Health Canada approves Adcetris in combination with AVD chemotherapy for the treatment of previously untreated Hodgkin's lymphoma ...
Posted by Michael Wonder on 03 May 2019
Cresemba now available in Canada for the treatment of invasive aspergillosis and invasive mucormycosis
2 May 2019 - AVIR Pharma is pleased to announce that Cresemba (isavuconazole, as isavuconazonium sulphate), an anti-fungal approved for the ...
Posted by Michael Wonder on 20 Apr 2019
Health Canada approves Skyrizi (risankizumab) for the treatment of moderate to severe plaque psoriasis
18 April 2019 - Approval of Skyrizi (risankizumab) is based on results from clinical studies showing significant improvement in levels of ...
Posted by Michael Wonder on 12 Apr 2019
Health Canada issues Notice of Compliance with Conditions for Libtayo (cemiplimab), the first and only biologic for the treatment of advanced cutaneous squamous cell carcinom
11 April 2019 - Cutaneous squamous cell carcinoma is the second most common skin cancer in Canada. ...
Posted by Michael Wonder on 11 Apr 2019
Teva Canada announces the approval of Truxima, the first biosimilar to Rituxan in Canada for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukaemia and rheumatoid arthritis
10 April 2019 - Teva Canada announces that Health Canada has granted a notice of compliance for Truxima (rituximab), the ...
Posted by Michael Wonder on 09 Apr 2019
Health Canada approves new drug to treat metastatic breast cancer through international and domestic joint reviews
9 April 2019 - Canadians want improved access to the most recent and innovative treatment options for themselves and their ...
Posted by Michael Wonder on 26 Mar 2019
Health Canada approves Cimzia (certolizumab pegol) for moderate-to-severe psoriasis
25 March 2019 - Health Canada also approves label updates in pregnancy and breast-feeding ...
Posted by Michael Wonder on 19 Mar 2019
New treatment option now available in Canada for newly diagnosed patients with advanced lung cancer
18 March 2019 - Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy reduced the risk of death by half compared ...
Posted by Michael Wonder on 13 Mar 2019
Foquest receives approval for expanded indication for children and adolescents with ADHD
12 March 2019 - First and only methylphenidate product approved in Canada that provides control of ADHD symptoms throughout the day. ...